CA2444347A1 - Method for treating gout and binding uric acid - Google Patents

Method for treating gout and binding uric acid Download PDF

Info

Publication number
CA2444347A1
CA2444347A1 CA002444347A CA2444347A CA2444347A1 CA 2444347 A1 CA2444347 A1 CA 2444347A1 CA 002444347 A CA002444347 A CA 002444347A CA 2444347 A CA2444347 A CA 2444347A CA 2444347 A1 CA2444347 A1 CA 2444347A1
Authority
CA
Canada
Prior art keywords
polymer
uric acid
solid
cross
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002444347A
Other languages
English (en)
French (fr)
Inventor
Stephen Randall Holmes-Farley
Steven K. Burke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2444347A1 publication Critical patent/CA2444347A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CA002444347A 2001-04-18 2002-04-10 Method for treating gout and binding uric acid Abandoned CA2444347A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
US60/284,445 2001-04-18
US30556701P 2001-07-13 2001-07-13
US60/305,567 2001-07-13
PCT/US2002/011492 WO2002085381A1 (en) 2001-04-18 2002-04-10 Method for treating gout and binding uric acid

Publications (1)

Publication Number Publication Date
CA2444347A1 true CA2444347A1 (en) 2002-10-31

Family

ID=26962624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002444347A Abandoned CA2444347A1 (en) 2001-04-18 2002-04-10 Method for treating gout and binding uric acid

Country Status (9)

Country Link
US (2) US20030039627A1 (https=)
EP (1) EP1416942B1 (https=)
JP (1) JP2004528332A (https=)
AT (1) ATE380553T1 (https=)
BR (1) BR0209133A (https=)
CA (1) CA2444347A1 (https=)
DE (1) DE60224052T2 (https=)
MX (1) MXPA03009571A (https=)
WO (1) WO2002085381A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
WO2004099288A1 (en) * 2003-05-09 2004-11-18 Carlsberg A/S Polyethyleneimine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP3000460A1 (en) 2005-09-15 2016-03-30 Genzyme Corporation Sachet formulation for amine polymers
EP1945196A2 (en) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesium-containing polymers for hyperphosphatemia
EP2016114A2 (en) * 2006-05-05 2009-01-21 Genzyme Corporation Amine condensation polymers as phosphate sequestrants
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
AU2007275711A1 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
KR20150024919A (ko) * 2006-11-13 2015-03-09 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
US8163799B2 (en) * 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
JP2010519298A (ja) * 2007-02-23 2010-06-03 ゲンズイメ コーポレーション アミンポリマー組成物
EP2131820A1 (en) * 2007-03-08 2009-12-16 Genzyme Corporation Sulfone polymer compositions
EP2152277A1 (en) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
WO2009078958A1 (en) * 2007-12-14 2009-06-25 Genzyme Corporation Coated pharmaceutical compositions
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
BR112019013364A2 (pt) 2016-12-28 2020-04-14 Fujifilm Corp emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
EP4164659B1 (en) * 2021-08-24 2024-03-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia
EP4161534B1 (en) * 2021-08-24 2024-11-06 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271191A (en) * 1979-12-19 1981-06-02 Pierre Fabre S.A. Method of treating hyperuricemia and gout
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
EP0934352B1 (en) * 1996-10-23 2007-05-02 Dow Global Technologies Inc. Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid

Also Published As

Publication number Publication date
US20030039627A1 (en) 2003-02-27
DE60224052D1 (de) 2008-01-24
EP1416942B1 (en) 2007-12-12
JP2004528332A (ja) 2004-09-16
EP1416942A1 (en) 2004-05-12
US20080112918A1 (en) 2008-05-15
DE60224052T2 (de) 2008-11-06
ATE380553T1 (de) 2007-12-15
MXPA03009571A (es) 2004-02-12
BR0209133A (pt) 2004-06-15
WO2002085381A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
EP1416942B1 (en) Amine polymers for treating gout and binding uric acid
US20020187120A1 (en) Method for treating gout and reducing serum uric acid
AU2002257145B2 (en) Method for lowering serum glucose
CA2349620C (en) Use of aliphatic polyamines for reducing oxalate
EP0996454B1 (en) Use of polyallylamine polymers for the manufacture of a medicament for treating hypercholesterolemia
US6566407B2 (en) Method for reducing oxalate
AU2002257145A1 (en) Method for lowering serum glucose
ZA200308063B (en) Method of lowering serum glucose.
US20020182168A1 (en) Method for reducing copper levels and treating copper toxicosis
US20020168333A1 (en) Method for improving vascular access in patients with vascular shunts
EP1923064B1 (en) Use of amine polymer for lowering serum glucose

Legal Events

Date Code Title Description
FZDE Discontinued